In vivo real-time tracking of single quantum dots conjugated with monoclonal anti-HER2 antibody in tumors of mice

Cancer Research

Volumn 67, Issue 3, 2007, Pages 1138-1144

  Tada, Hiroshi ^a   Higuchi, Hideo ^b   Wanatabe, Tomonobu M ^b   Ohuchi, Noriaki ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TOHOKU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; QUANTUM DOT; TRASTUZUMAB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DIFFUSION; DRUG EFFICACY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS;

ANIMALS; ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MEMBRANE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MICE; MICROSCOPY, CONFOCAL; QUANTUM DOTS; RECEPTOR, ERBB-2;

EID: 33847018888     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-1185     Document Type: Article

References (29)

1. Mamot C, Drummond DC, Noble CO, et al. Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. Cancer Res 2005;65:11631-8.
2. Torchilin VP, Lukyanov AN, Gao Z, Papahadjopoulos-Sternberg B. Immunomicelles: targeted pharmaceutical carriers for poorly soluble drugs. Proc Natl Acad Sci U S A 2003;100:6039-44.
3. Krauss WC, Park JW, Kirpotin DB, Hong K, Benz CC. Emerging antibody-based HER2 (ErbB-2/neu) therapeutics. Breast Dis 2000;11:113-24.
4. Ishijima A, Kojima H, Funatsu T, et al. Simultaneous observation of individual ATPase and mechanical events by a single myosin molecule during interaction with actin. Cell 1998;92:161-71.
5. Lyons SK. Advances in imaging mouse tumour models in vivo. J Pathol 2005;205:194-205.
6. Wu X, Liu H, Liu J, et al. Immunofluorescent labeling of cancer marker Her2 and other cellular targets with semiconductor quantum dots. Nat Biotechnol 2003;21:41-6.
7. Bruchez M, Jr., Moronne M, Gin P, Weiss S, Alivisatos AP. Semiconductor nanocrystals as fluorescent biological labels. Science 1998;281:2013-6.
8. Gao X, Cui Y, Levenson RM, Chung LW, Nie S. In vivo cancer targeting and imaging with semiconductor quantum dots. Nat Biotechnol 2004;22:969-76.
9. Endow SA, Higuchi H. A mutant of the motor protein kinesin that moves in both directions on microtubules. Nature 2000;406:913-6.
10. Yildiz A Forkey JN, McKinney SA Ha T, Goldman YE, Selvin PR. Myosin V walks hand-over-hand: single fluorophore imaging with 1.5-nm localization. Science 2003;300:2061-5.
11. Dahan M, Levi S, Luccardini C, Rostaing P, Riveau B, Triller A. Diffusion dynamics of glycine receptors revealed by single-quantum dot tracking. Science 2003;302:442-5.
12. Lidke DS, Nagy P, Heintzmann R, et al. Quantum dot ligands provide new insights into erbB/HER receptor-mediated signal transduction. Nat Biotechnol 2004;22:198-203.
13. Leunig M, Yuan F, Menger MD, et al. Angiogenesis, microvascular architecture, microhemodynamics, and interstitial fluid pressure during early growth of human adenocarcinoma LS174T in SCID mice. Cancer Res 1992;52:6553-60.
14. Chong FK, Coates CG, Denvir DJ, McHale NG, Thornvury KD, Hollywood MK. Optimization of spinning disk confocal microscopy: synchronization with the ultra-sensitive EMCCD. Proc SPIE 2004;5324:65-76.
15. Kurebayashi J, Otsuki T, Tang CK, et al. Isolation and characterization of a new human breast cancer cell line, KPL-4, expressing the Erb B family receptors and interleukin-6. Br J Cancer 1999;79:707-17.
16. Fujimoto-Ouchi K, Sekiguchi F, Tanaka Y. Antitumor activity of combinations of anti-HER-2 antibody trastuzumab and oral fluoropyrimidines capecitabine/5′-dFUrd in human breast cancer models. Cancer Chemother Pharmacol 2002;49:211-6.
17. Nguyen VT, Kamio Y, Higuchi H. Single-molecule imaging of cooperative assembly of γ-hemolysin on erythrocyte membranes. EMBO J 2003;22:4968-79.
18. Nguyen H, Higuchi H. Motility of myosin V regulated by the dissociation of single calmodulin. Nat Struct Mol Biol 2005;12:127-32.
19. Park JW, Kirpotin DB, Hong K, et al. Tumor targeting using anti-her2 immunoliposomes. J Control Release 2001;74:95-113.
20. Ballangrud AM, Yang WH, Palm S, et al. α-Particle emitting atomic generator (Actinium-225)-labeled trastuzumab (Herceptin) targeting of breast cancer spheroids: efficacy versus HER2/neu expression. Clin Cancer Res 2004;10:4489-97.
21. Wiercioch R, Balcerczak E, Byszewska E, Mirowski M. Uptake of radiolabelled Herceptin by experimental mammary adenocarcinoma. Nucl Med Rev Cent East Eur 2003;6:99-103.
22. Braun RD, Abbas A, Bukhari SO, Wilson W III. Hemodynamic parameters in blood vessels in choroidal melanoma xenografts and rat choroid. Invest Ophthalmol Vis Sci 2002;43:3045-52.
23. Carraway CA, Carvajal ME, Carraway KL. Association of the Ras to mitogen-activated protein kinase signal transduction pathway with microfilaments. Evidence for a p185(neu)-containing cell surface signal transduction particle linking the mitogenic pathway to a membrane-microfilament association site. J Biol Chem 1999;274:25659-67.
24. Buss F, Arden SD, Lindsay M, Luzio JP, Kendrick-Jones J. Myosin VI isoform localized to clathrin-coated vesicles with a role in clathrin-mediated endocytosis. EMBO J 2001;20:3676-84.
25. Aschenbrenner L, Naccache SN, Hasson T. Uncoated endocytic vesicles require the unconventional myosin, Myo6, for rapid transport through actin barriers. Mol Biol Cell 2004;15:2253-63.
26. Kamal A, Goldstein LS. Connecting vesicle transport to the cytoskeleton. Curr Opin Cell Biol 2000;12:503-8.
27. Mross K, Niemann B. Massing U, et al. Pharmacokinetics of liposomal doxorubicin (TLC-D99; Myocet) in patients with solid tumors: an open-label, single-dose study. Cancer Chemother Pharmacol 2004;54:514-24.
28. O'Brien ME, Wigler N, Inbar M, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 2004;15:440-9.
29. Hamaguchi T, Matsumura Y, Nakanishi Y, et al. Antitumor effect of MCC-465, pegylated liposomal doxorubicin tagged with newly developed monoclonal antibody GAH, in colorectal cancer xenografts. Cancer Sci 2004;95:608-13.